Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of April 2025, specifically detailing share repurchases executed on April 9, 2025. The filing is made pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases executed as part of an existing buyback program. The following metrics summarize the transaction:
- Date of Purchase: April 9, 2025
- Aggregate Shares Purchased: 1,519,276 ordinary shares
- Lowest Price Paid: 1,243.50 GBp
- Highest Price Paid: 1,308.50 GBp
- Volume-Weighted Average Price (VWAP): 1,264.07 GBp
- Trading Venue: London Stock Exchange (XLON)
- Broker: Citigroup Global Markets Limited
Since the commencement of the non-discretionary agreement on February 24, 2025, the Company has purchased a total of 25,241,913 ordinary shares. Following the April 9 transaction, GSK holds 194,312,216 ordinary shares in treasury. The total number of ordinary shares in issue (excluding treasury shares) is 4,120,914,866, which equals the total number of voting rights.
Material Changes and Program Status
The purchase of 1,519,276 shares represents a continuation of the buyback program announced on February 24, 2025. There are no material changes to the program's structure or authorization noted in this filing; the transaction was executed pursuant to the existing non-discretionary agreement with the broker. The filing does not provide data on revenue, profit, cash flow, or debt levels, as it is strictly a report of a share transaction.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,120,914,866) to confirm the denominator for calculating shareholder interest notifications under FCA Disclosure Guidance and Transparency Rules.
- Confirm the cumulative buyback volume of 25,241,913 shares since February 24, 2025, against the total authorized buyback amount (not specified in this filing).
- Note that the purchased shares are held as Treasury shares and do not carry voting rights.
- Review the GSK 2024 Annual Report on Form 20-F for the full list of risk factors referenced in the cautionary statement.